Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | TLR4 | O00206 | 6/20 | 0.36 |
| ▸ | PRKCA | P17252 | 5/20 | 0.36 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19583432 | 1.00 | CA2 (0.59) | CA2CA9TLR4PRKCALY96 | |
| SCHEMBL19583440 | 1.00 | CA2 (0.59) | CA2CA9TLR4PRKCALY96 | |
| Sucralose SCHEMBL3953863 | 0.84 | CA2 (0.72) | CA2CA9PRKCA | |
| SCHEMBL128339 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL359292 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL313538 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL39624 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL15435964 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL337163 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 | |
| SCHEMBL359493 | 0.81 | LDHA (0.48) | TLR4PRKCALY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10279050-B2 | Sucrose ester based cationic gene vector and preparation method thereof | DALIAN NATIONALITIES UNIVERSITY (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20170326255-A1 | SUCROSE ESTER BASED CATIONIC GENE VECTOR AND PREPARATION METHOD THEREOF | DALIAN NATIONALITIES UNIVERSITY (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9732108-B2 | Halogenated di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | COMMON PHARMA | 2017-08-15 | — | — | US | disclosed |
| EP-2077847-B1 | SUCRALOSE MONOLAURATE AND SUCRALOSE MONOMYRISTATE, PHARMACEUTICAL FORMULATIONS, DIAGNOSTIC KITS AND METHODS OF TREATMENT | MEMARZADEH BAHRAM (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2077847-B1 | SUCRALOSE MONOLAURATE AND SUCRALOSE MONOMYRISTATE, PHARMACEUTICAL FORMULATIONS, DIAGNOSTIC KITS AND METHODS OF TREATMENT | MEMARZADEH BAHRAM (US) | 2016-02-24 | — | — | EP | disclosed |
| US-20140065062-A1 | Halogenated Di and Trisaccharides, Pharmaceutical Formulations, Diagnostic Kits and Methods of Treatment | COMMON PHARMA | 2014-03-06 | — | — | US | disclosed |
| US-8575333-B2 | Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | COMMON PHARMA | 2013-11-05 | — | — | US | disclosed |
| US-20090318381-A1 | Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | COMMON PHARMA | 2009-12-24 | — | — | US | disclosed |
| EP-2077847-A2 | HALOGENATED ALKYL DI- AND TRISACCHARIDES, PHARMACEUTICAL FORMULATIONS, DIAGNOSTIC KITS AND METHODS OF TREATMENT | Memarzadeh, Bahram (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080171721-A1 | Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | MEMARZADEH BAHRAM | 2008-07-17 | — | — | US | disclosed |
| WO-2008033543-A9 | HALOGENATED ALKYL DI- AND TRISACCHARIDES, PHARMACEUTICAL FORMULATIONS, DIAGNOSTIC KITS AND METHODS OF TREATMENT | MEMARZADEH BAHRAM (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008033543-A2 | HALOGENATED ALKYL DI- AND TRISACCHARIDES, PHARMACEUTICAL FORMULATIONS, DIAGNOSTIC KITS AND METHODS OF TREATMENT | MEMARZADEH BAHRAM (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318381-A1 | Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | FUCA2, UGDH, UGCG | CA2 630/4885CA9 342/4885TLR4 695/4885 |
| US-20170326255-A1 | SUCROSE ESTER BASED CATIONIC GENE VECTOR AND PREPARATION METHOD THEREOF | CETP, NPC1L1, LIPA | CA2 3579/4885CA9 2361/4885TLR4 285/4885 |
| US-10279050-B2 | Sucrose ester based cationic gene vector and preparation method thereof | CETP, NPC1L1, LIPA | CA2 3579/4885CA9 2361/4885TLR4 285/4885 |
| US-20080171721-A1 | Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment | FUCA2, UGDH, UGCG | CA2 630/4885CA9 342/4885TLR4 695/4885 |
| US-20140065062-A1 | Halogenated Di and Trisaccharides, Pharmaceutical Formulations, Diagnostic Kits and Methods of Treatment | UGDH, UGCG, FUCA2 | CA2 408/4885CA9 177/4885TLR4 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.